Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 3.27 0.00% 0.00
TCON closed up 1.87 percent on Tuesday, November 19, 2019, on 30 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical TCON trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 1.87%
Inside Day Range Contraction 1.87%
Wide Bands Range Expansion 1.87%
Oversold Stochastic Weakness 1.87%
Wide Bands Range Expansion 4.81%
Down 3 Days in a Row Weakness 4.81%

Older signals for TCON ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Medicine Biopharmaceutical Health Cancer Drugs Clinical Trial Breast Cancer Colorectal Cancer Targeted Therapy Glioblastoma Age Related Macular Degeneration Hepatocellular Carcinoma Lung Cancer Renal Cell Carcinoma Therapeutics For Cancer Fibrotic Diseases Ros1 Transgene Sa
Is TCON a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.8
52 Week Low 2.781
Average Volume 24,945
200-Day Moving Average 7.0409
50-Day Moving Average 3.9022
20-Day Moving Average 3.6263
10-Day Moving Average 3.4869
Average True Range 0.4383
ADX 39.98
+DI 6.5758
-DI 28.0458
Chandelier Exit (Long, 3 ATRs ) 3.5461
Chandelier Exit (Short, 3 ATRs ) 4.0959
Upper Bollinger Band 4.489
Lower Bollinger Band 2.7636
Percent B (%b) 0.29
BandWidth 47.580178
MACD Line -0.1696
MACD Signal Line -0.1174
MACD Histogram -0.0522
Fundamentals Value
Market Cap 54.47 Million
Num Shares 16.7 Million
EPS -1.75
Price-to-Earnings (P/E) Ratio -1.87
Price-to-Sales 17.03
Price-to-Book 2.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.43
Resistance 3 (R3) 3.42 3.36 3.40
Resistance 2 (R2) 3.36 3.32 3.36 3.39
Resistance 1 (R1) 3.31 3.29 3.34 3.32 3.38
Pivot Point 3.25 3.25 3.26 3.26 3.25
Support 1 (S1) 3.21 3.21 3.23 3.22 3.16
Support 2 (S2) 3.15 3.19 3.15 3.15
Support 3 (S3) 3.10 3.15 3.14
Support 4 (S4) 3.11